Blog

Cleveland Clinic has entered into an agreement with DASI Simulations to co-develop the next generation of AI predictive modeling solutions for the treatment of structural heart diseases. Cleveland Clinic also will utilize DASI’s existing technology to support planning and treatment for current TAVR patients at Cleveland Clinic.

Transcatheter Aortic Valve Replacement (TAVR) is a minimally invasive procedure to replace a diseased aortic valve with an artificial valve without the need for open-heart surgery.

“We’re committed to innovating in the cardiovascular field for both patients and providers, and this relationship will elevate the standard of TAVR care for heart care providers across the country,” said Samir Kapadia, M.D., chairman of Cardiovascular Medicine at Cleveland Clinic. “Developing our models to guide TAVR during the procedure with the help of AI will allow us to further enhance the safety of the procedure and ensure optimal valve selection.”

As part of a two-year co-development partnership, DASI and Cleveland Clinic are working to develop innovative AI technology that can assist doctors in real time during heart procedures. By combining Cleveland Clinic’s clinical expertise and extensive data with DASI’s advanced AI models, the goal is to create the world’s first AI-powered “co-pilot” system for catheterization labs.

“Partnering with Cleveland Clinic allows us to bring the power of AI-driven, physics-based simulation directly into current clinical practice,” says DASI Founder and CEO Teri Sirset. “Together, we are pioneering a new era of personalized medicine through co-product development, transforming how structural heart procedures are planned and executed to improve patient outcomes and drive innovation in cardiovascular care.”

“This partnership marks a major milestone for DASI and for the field. It validates our vision of advanced predictive modeling as the future of decision-making in structural heart therapies, while taking a bold step toward real-time physician decision support,” said Lakshmi (Prasad) Dasi, Ph.D., FACC, FAIMBE, founder and chief technology officer of DASI. “With our next-generation products, I see us truly democratizing decision-making in structural heart procedures—enabling the highest quality care, improving outcomes and ultimately reducing healthcare costs.”

The current DASI Simulations technology, which will be employed at Cleveland Clinic, is a novel AI-powered medical platform that changes routine imaging, such as a CT scan, into a four-dimensional predictive environment to help physicians personalize their treatment approach to optimize the outcome for patients.

The company’s first product, PrecisionTAVI™, is the only FDA-cleared product with a CMS reimbursement code in this specialized domain of structural heart therapies. The AI-powered DASI technology, coupled with computational modeling, has consistently demonstrated improvements in patient outcomes.

In addition to this collaboration, Cleveland Clinic is an investor in DASI Simulations and may benefit financially from the sale of this technology.

MEDIA CONTACTS:

Cleveland Clinic: Hope Buggey 216.213.6192, buggeyh@ccf.org

DASI Simulations: Kelly Arledge 614.205.0339, kellyarledge@kwapr.com